A
AKRO

AlphaQuest’s Akero Therapeutics AKRO Stock Holding History

AlphaQuest’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-9,186
Closed -$436K – 2249
2025
Q3 		$436K Buy
9,186
+2,012
+28% +$97.4K 0.03% 886
2025
Q2 		$383K Sell
7,174
-2,442
-25% -$111K 0.04% 750
2025
Q1 		$389K Buy
9,616
+1,444
+18% +$61.2K 0.04% 641
2024
Q4 		$227K Buy
8,172
+8,147
+32,588% +$247K 0.03% 817
2024
Q3 		$717 Sell
25
-12,584
-100% -$328K ﹤0.01% 1653
2024
Q2 		$296K Buy
12,609
+12,552
+22,021% +$268K 0.04% 637
2024
Q1 		$1.44K Sell
57
-3,162
-98% -$75.9K ﹤0.01% 1135
2023
Q4 		$75.2K Buy
+3,219
New +$63.5K 0.02% 820

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

AlphaQuest's AKRO Position: Q4 2025 in Review

AlphaQuest sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 9,186 shares — an estimated $436K sold.

AlphaQuest first reported a position in AKRO in Q4 2023 and held it in 8 quarters. The position peaked at $436K in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • AlphaQuest reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • AlphaQuest sold 9,186 Akero Therapeutics shares in Q4 2025, an estimated $436K.
  • AlphaQuest first reported a position in Akero Therapeutics in Q4 2023 and held it in 8 quarters.
  • AlphaQuest's Akero Therapeutics position peaked at $436K in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on AlphaQuest's 13F filing for Q4 2025, filed 9 Feb 2026.